The University of Chicago Header Logo

Connection

Mary Elizabeth Strek to Idiopathic Pulmonary Fibrosis

Back to Details
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Idiopathic Pulmonary Fibrosis.
Mary Elizabeth Strek
Connection Strength
8.072
Idiopathic Pulmonary Fibrosis
  1. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
    View in: PubMed
    Score: 0.676
  2. Vessel-related structures predict UIP pathology in those with a non-IPF pattern on CT. Eur Radiol. 2021 Oct; 31(10):7295-7302.
    View in: PubMed
    Score: 0.542
  3. Gender in idiopathic pulmonary fibrosis diagnosis: time to address unconscious bias. Thorax. 2020 05; 75(5):365-366.
    View in: PubMed
    Score: 0.505
  4. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019 Sep 06; 20(1):205.
    View in: PubMed
    Score: 0.485
  5. CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. AJR Am J Roentgenol. 2018 May; 210(5):1034-1041.
    View in: PubMed
    Score: 0.438
  6. CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. AJR Am J Roentgenol. 2018 Feb; 210(2):307-313.
    View in: PubMed
    Score: 0.428
  7. Radiologic Features of Airways Disease Are Associated With Interstitial Lung Abnormality Progression. Respir Care. 2026 Apr; 71(4):390-396.
    View in: PubMed
    Score: 0.190
  8. A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2025 10; 211(10):1785-1793.
    View in: PubMed
    Score: 0.185
  9. Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 10; 211(10):1823-1834.
    View in: PubMed
    Score: 0.185
  10. Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. Am J Respir Crit Care Med. 2024 09 01; 210(5):639-647.
    View in: PubMed
    Score: 0.171
  11. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. Am J Respir Crit Care Med. 2024 08 15; 210(4):455-464.
    View in: PubMed
    Score: 0.171
  12. Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 05 01; 209(9):1111-1120.
    View in: PubMed
    Score: 0.167
  13. A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis. J Heart Lung Transplant. 2024 07; 43(7):1174-1182.
    View in: PubMed
    Score: 0.166
  14. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023 11; 62(5).
    View in: PubMed
    Score: 0.162
  15. Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis. Chest. 2024 03; 165(3):621-631.
    View in: PubMed
    Score: 0.161
  16. Tobacco smoking is associated with combined pulmonary fibrosis and emphysema and worse outcomes in interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2023 08 01; 325(2):L233-L243.
    View in: PubMed
    Score: 0.158
  17. PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023 06 01; 207(11):1515-1524.
    View in: PubMed
    Score: 0.157
  18. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31; 24(1):141.
    View in: PubMed
    Score: 0.157
  19. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 2023 05; 163(5):1156-1165.
    View in: PubMed
    Score: 0.153
  20. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study. Lancet Respir Med. 2023 01; 11(1):65-73.
    View in: PubMed
    Score: 0.149
  21. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022 06; 59(6).
    View in: PubMed
    Score: 0.147
  22. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis. Respirology. 2022 08; 27(8):635-644.
    View in: PubMed
    Score: 0.146
  23. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022 05 01; 205(9):e18-e47.
    View in: PubMed
    Score: 0.146
  24. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022 09; 162(3):603-613.
    View in: PubMed
    Score: 0.145
  25. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30; 22(1):257.
    View in: PubMed
    Score: 0.140
  26. Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. Am J Respir Crit Care Med. 2021 07 15; 204(2):197-208.
    View in: PubMed
    Score: 0.138
  27. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest. 2020 10; 158(4):1526-1534.
    View in: PubMed
    Score: 0.127
  28. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020 03 01; 201(5):564-574.
    View in: PubMed
    Score: 0.125
  29. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 07 15; 200(2):199-208.
    View in: PubMed
    Score: 0.120
  30. Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 10; 156(4):715-723.
    View in: PubMed
    Score: 0.119
  31. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulm Med. 2018 Feb 08; 18(1):30.
    View in: PubMed
    Score: 0.109
  32. CT findings associated with survival in chronic hypersensitivity pneumonitis. Eur Radiol. 2017 Dec; 27(12):5127-5135.
    View in: PubMed
    Score: 0.104
  33. ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol. 2018 01; 11(1):61-70.
    View in: PubMed
    Score: 0.103
  34. Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest. 2016 Dec; 150(6):1371-1386.
    View in: PubMed
    Score: 0.098
  35. Response. Chest. 2016 Feb; 149(2):600-601.
    View in: PubMed
    Score: 0.094
  36. Treatment of Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2016 Jan; 13(1):115-7.
    View in: PubMed
    Score: 0.094
  37. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015 Dec 15; 192(12):1475-82.
    View in: PubMed
    Score: 0.094
  38. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015 Nov 21; 15:147.
    View in: PubMed
    Score: 0.093
  39. Thyroid Disease Is Prevalent and Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2015 Sep; 148(3):692-700.
    View in: PubMed
    Score: 0.092
  40. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
    View in: PubMed
    Score: 0.084
  41. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
    View in: PubMed
    Score: 0.078
  42. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):344-51.
    View in: PubMed
    Score: 0.069
  43. Comprehensive assessment of complete blood count as a prognostic biomarker in interstitial lung diseases. Respir Med. 2026 Oct; 262:109086.
    View in: PubMed
    Score: 0.049
  44. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 08; 211(8):1452-1462.
    View in: PubMed
    Score: 0.046
  45. Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease. Am J Respir Crit Care Med. 2024 08 15; 210(4):444-454.
    View in: PubMed
    Score: 0.043
  46. Deep Learning Classification of Usual Interstitial Pneumonia Predicts Outcomes. Am J Respir Crit Care Med. 2024 05 01; 209(9):1121-1131.
    View in: PubMed
    Score: 0.042
  47. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med. 2017 02; 123:56-62.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.